Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALY688-SR in Healthy Overweight or Obese Adults
NCT04855565Phase 1Terminated
- Sponsor
- Allysta Pharmaceuticals
- Start
- May 2021
- Primary completion
- Aug 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALY688 in Overweight and obesity (2 arms), sponsored by Allysta Pharmaceuticals. Primary endpoint: Change between pre- and post-intervention safety and tolerability assessments at 16 days. Started May 2021; status: terminated.
02
Drugs
ALY688
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT04855565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855565.